NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company’s lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer’s, as well as under preclinical studies for the treatment of Parkinson’s disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer’s disease. The company was incorporated in 2017 and is headquartered in Herzliya, Israel.
Metrics to compare | NRSN | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipNRSNPeersSector | |
---|---|---|---|---|
P/E Ratio | −3.0x | −2.7x | −0.5x | |
PEG Ratio | −0.09 | −0.03 | 0.00 | |
Price/Book | −50.2x | 1.8x | 2.6x | |
Price / LTM Sales | - | 11.3x | 3.3x | |
Upside (Analyst Target) | - | 733.3% | 38.9% | |
Fair Value Upside | Unlock | 12.0% | 5.4% | Unlock |